Start over please. Create a chronological list of recent pharmaceutical news

1. **September 20, 2024**: The pharmaceutical cleaning validation market is expected to reach USD 28.40 billion by 2030, growing at a CAGR of 6.7% from 2024 to 2030. This growth is driven by the increasing demand for pharmaceuticals, the rising number of approvals for new drugs, and the implementation of stringent cleaning validation standards.
2. **September 11, 2024**: The Indian pharmaceutical market is expected to reach USD 106.67 billion by 2030, growing at a CAGR of 8.75% from 2024 to 2030. This expansion is supported by the domestic market's robust growth and the industry's prominence as a global hub for pharmaceutical manufacturing and innovation.
3. **August 30, 2024**: Rekah Pharmaceutical Industry (TLV:REKA) reported a net income of ₪12.0 million, up from ₪1.10 million in 2Q 2023, driven by lower expenses.
4. **August 15, 2024**: Biofrontera Inc. (NASDAQ:BFRI) reported a net income of $-257,000 and a total revenue of $7.84 million for Q2 2024, resulting in a diluted EPS of $-0.05.
5. **August 14, 2024**: The FDA has decided to waive the scheduled Advisory Committee meeting for sulopenem, signaling confidence in the drug’s safety and efficacy profile.
6. **August 9, 2024**: The UK pharmaceutical preparations manufacturing industry is expected to grow at a compound annual rate of 6.5% over the next five years, driven by domestic demand and the benefits of the COVID-19 pandemic.
7. **August 6, 2024**: Travere Therapeutics (NASDAQ:TVTX) reported a net loss of $-70.41 million and a total revenue of $54.12 million for Q2 2024, resulting in a diluted EPS of $-0.91.
8. **August 3, 2024**: Applied Therapeutics (NASDAQ:APLT) reported a net income of $2.9 million and a total revenue of $144 million for Q2 2024, resulting in a diluted EPS of $-0.13.
9. **July 31, 2024**: The FDA has reaffirmed the PDUFA target action date for govorestat, which could be a significant milestone for Applied Therapeutics.
10. **July 18, 2024**: Citigroup raised the price target for Travere Therapeutics from $14.00 to $23.00, and the stock price increased by 5.9% in response.

This chronological list provides a comprehensive overview of recent developments in the pharmaceutical industry, including market growth, company financials, and regulatory updates.